InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Protara Therapeutics, Inc.

TARA Clue Score25
United States Fiscal year ends December CIK 0001359931
$2.76 +3.96% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $2.76 −59.19% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 12 Oct 2016. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2016Operating income−28.7Net income−28.5Fiscal year 2017Operating income−30.4Net income−30.0Fiscal year 2018Operating income−21.4Net income−20.7Fiscal year 2019Operating income−7.8Net income−7.8Fiscal year 2020Operating income−34.4Net income−34.0Fiscal year 2021Operating income−47.5Net income−47.3EPS, diluted−4.21Fiscal year 2022Operating income−67.1Net income−66.0EPS, diluted−5.86Fiscal year 2023Operating income−43.6Net income−40.4EPS, diluted−3.57Fiscal year 2024Operating income−49.2Net income−44.6EPS, diluted−2.17Fiscal year 2025Operating income−64.5Net income−57.4EPS, diluted−1.34
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating income −28.7 −30.4 −21.4 −7.8 −34.4 −47.5 −67.1 −43.6 −49.2 −64.5
Net income −28.5 −30.0 −20.7 −7.8 −34.0 −47.3 −66.0 −40.4 −44.6 −57.4
Growth
EPS, diluted n/a n/a n/a n/a n/a −4.21 −5.86 −3.57 −2.17 −1.34

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2016Operating cash flow−23.7Capital expenditure−0.3Free cash flow−24.0Fiscal year 2017Operating cash flow−22.4Capital expenditure−0.0Free cash flow−22.4Fiscal year 2018Operating cash flow−23.2Capital expenditure−0.1Free cash flow−23.4Fiscal year 2019Operating cash flow−5.0Capital expenditure−0.5Free cash flow−5.5Fiscal year 2020Operating cash flow−23.4Capital expenditure−0.9Free cash flow−24.3Fiscal year 2021Operating cash flow−34.5Capital expenditure−0.6Free cash flow−35.1Buybacks−0.2Fiscal year 2022Operating cash flow−26.5Capital expenditure−0.1Free cash flow−26.6Buybacks−0.1Fiscal year 2023Operating cash flow−37.6Capital expenditure−0.0Free cash flow−37.6Buybacks−0.1Fiscal year 2024Operating cash flow−35.8Capital expenditure−0.1Free cash flow−35.9Fiscal year 2025Operating cash flow−56.4Capital expenditure−0.1Free cash flow−56.5
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −23.7 −22.4 −23.2 −5.0 −23.4 −34.5 −26.5 −37.6 −35.8 −56.4
Capital expenditure −0.3 −0.0 −0.1 −0.5 −0.9 −0.6 −0.1 −0.0 −0.1 −0.1
Free cash flow −24.0 −22.4 −23.4 −5.5 −24.3 −35.1 −26.6 −37.6 −35.9 −56.5
Growth
Buybacks n/a n/a n/a n/a n/a −0.2 −0.1 −0.1 n/a n/a

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2016Cash36.4Shareholders’ equity38.4Fiscal year 2017Cash21.2Shareholders’ equity34.7Fiscal year 2018Cash19.4Shareholders’ equity4.8Fiscal year 2019Cash0.6Shareholders’ equity−2.1Fiscal year 2020Cash168.6Shareholders’ equity199.2Fiscal year 2021Cash35.7Shareholders’ equity161.9Fiscal year 2022Cash24.1Shareholders’ equity102.1Fiscal year 2023Cash39.6Shareholders’ equity68.3Fiscal year 2024Cash162.8Shareholders’ equity167.1Fiscal year 2025Cash49.7Shareholders’ equity196.4
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 36.4 21.2 19.4 0.6 168.6 35.7 24.1 39.6 162.8 49.7
Shareholders’ equity 38.4 34.7 4.8 −2.1 199.2 161.9 102.1 68.3 167.1 196.4

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2016 31 Dec 2016 FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024† 31 Dec 2024 FY2025† 31 Dec 2025
Revenue and profit
18.9 21.7 11.8 3.9 12.0 21.1 16.8 25.0 31.7 42.6
9.8 8.7 9.5 4.0 22.5 26.4 20.7 18.6 17.5 21.9
−28.7 −30.4 −21.4 −7.8 −34.4 −47.5 −67.1 −43.6 −49.2 −64.5
Growth
−28.5 −30.0 −20.7 −15.0 n/a n/a n/a n/a 44.6 57.4
−28.5 −30.0 −20.7 −7.8 −34.0 −47.3 −66.0 −40.4 −44.6 −57.4
Growth
Per share
n/a n/a n/a n/a n/a −4.21 −5.86 −3.57 −2.17 −1.34
n/a n/a n/a n/a n/a −4.21 −5.86 −3.57 −2.17 −1.34
Growth
n/a n/a n/a n/a n/a n/a 11.3 11.3 20.6 42.8
n/a n/a n/a n/a n/a 11.2 11.3 11.3 20.6 42.8
Growth +0.2% +0.6% +81.7% +108.0%

† The diluted share count jumps at 2024 and 2025, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 10 of 10 years on file.